Biotinylated Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Complex Protein (Monomer, MALS verified)

Wilms tumor gene 1 (WT1) ，is an attractive target antigen for leukemia and solid cancer. WT1-specific adoptive immunotherapy has developed for tumor treatment in recent years. WT1 has been proved wildly expressed in breast, colon and ovarian cancer. It participates in cell growth, differentiation and apoptosis regulation. The WT1127-134 (RMFPNAPYL) was shown to be recognized by HLA-A*0201 tumor-infiltrating lymphocytes from melanoma patients, and therefore it is widely been studied in TCR-T studies. The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1.

Biotinylated Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Complex Protein is produced by co-expression of HLA and B2M loaded with WT-1 peptide. This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 36.0 kDa and 13.9 kDa. The protein migrates as 42-45 kDa and 14 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

● -20°C to -70°C for 12 months in lyophilized state; ● -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Immobilized Biotinylated Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Complex Protein (Cat. No. HLW-H82E5) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.0005-0.49 ng/mL ng/mL (QC tested).